Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to Be at Imminent Risk for Suicide; https://clinicaltrials.gov/study/NCT03185819.
Authors
- Melissa P. DelBello (ORCID: https://orcid.org/0000-0003-1837-4126)
- Carla M. Canuso (ORCID: https://orcid.org/0000-0001-6817-9105)
- Wayne C. Drevets (ORCID: https://orcid.org/0000-0002-5097-3930)
- Colette Kosik‐Gonzalez
- Li Nancy Chen
- Dong‐Jing Fu (ORCID: https://orcid.org/0000-0001-6829-0743)
- Michael H. Bloch (ORCID: https://orcid.org/0000-0003-0352-4080)
- Carmen Moreno (ORCID: https://orcid.org/0000-0003-0541-4846)
- Rosanne Lane
Institutions
- Johnson & Johnson (United States) (US)
- Instituto de Salud Carlos III (ES)
- Hospital General Universitario Gregorio Marañón (ES)
- Yale University (US)
- Centro de Investigación Biomédica en Red de Salud Mental (ES)
- Janssen (United States) (US)
- University of Cincinnati Medical Center (US)
Publication Details
- Journal
- Journal of the American Academy of Child & Adolescent Psychiatry
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1016/j.jaac.2025.02.015
- Citations
- 8
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 11.16
Funders
- Janssen Research and Development